–
Kyverna Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−26.3
FY22:
−29.4
FY23:
−62.4
FY24:
−143
FY25:
−170
(positive)
Change from FY21 to FY25
millions USD
FY21:
−25.8
FY22:
−27.8
FY23:
−58.5
FY24:
−125
FY25:
−159
(positive)
Change from FY21 to FY25
millions USD
FY21:
−26.4
FY22:
−28.9
FY23:
−60.4
FY24:
−127
FY25:
−161
(positive)
Change from FY21 to FY25
millions USD
FY21:
−26.4
FY22:
−28.9
FY23:
−60.4
FY24:
−127
FY25:
−161
All amounts in millions USD FY21, FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.